Amgen and Horizon reached a deal for a price of $27.8 billion, or $116.50 per share.
Horizon Therapeutics (HZNP) is a pharmaceutical company that develops and markets treatments for rare diseases. Founded in 2005, the company has grown to become a leading global provider of rare disease treatments, with a portfolio of over 20 medicines and therapies. HZNP's products are used to treat various conditions, including respiratory and metabolic disorders, arthritis, and ophthalmic diseases. They are sold in over 40 countries and are particularly popular in the US and Europe.
In 2019, HZNP acquired Raptor Pharmaceuticals for $800 million, adding four approved therapies and a pipeline of development programs to its portfolio. HZNP is known for its medication Tepezza, which treats thyroid eye conditions, as well as Uplizna, which treats an inflammatory condition of the spinal cord and optic nerves, and Krystexxa, a medication for persistent gout.
HZNP has a strong financial position, with a strong balance sheet, no debt, and strong cash flow, making it well-positioned for future growth. The company is also investing in research and development to bring new treatments to those suffering from rare diseases. HZNP's stock price has been steadily increasing since it was first listed on the NASDAQ in 2014 and has gained over 300% in the past five years, making it a top performer in the healthcare sector.
Bidding Closed on HZNP
On Nov. 30, the day after it disclosed the prospective acquisition offers, HZNP stock experienced a surge. In the days since shares have been trending higher. The three-day sprint was reversed on the following Monday, although shares are still above their important moving averages. The reverse was due to Johnson & Johnson (JNJ) dropping out of the bidding process.
HZNP also received acquisition offers from Amgen (AMGN) and Sanofi SNY), with the deadline for each company to decide whether to submit an offer set for January 10, 2023. However already on December 10th, 2022, Amgen and Horizon reached a deal for a price of $27.8 billion, or $116.50 per share in cash. This is the biggest pharma merger of the year. It's also Amgen's most lucrative acquisition to date because Tepezza, a top-selling medication for thyroid eye disease, is now available to them.
AI Trading
Amagen wasn't the only one to recognize HZNP value. Our artificial intelligence recognized the company's value and published buy signals at various time horizons. The main advantage of using AI for stock market research is that it can examine more assets objectively and continuously at all times of the day to help you to make a profit consistently even in a bear market. You can improve decision-making, outcome modeling and forecasting, and collecting market information by combining big data analytics with our AI prediction system.
Below is our stock pick from our 1 month stock forecast publicly announcing HZNP as a buy on Friday, November 14th, 2022 to our subscribers getting exclusive market insights based on artificial intelligence. HZNP was the number four stock pick for this time frame and generated over a 50% ROI in one month and this was all before the ink was dry. Subscribe today to unleash the power of AI trading for your stock market analysis to enhance your portfolio
This stock pick has been available in multiple forecasts continuously over various time frames in November. HZNP has also been featured in another article we recently wrote where our proprietary AI-powered stock prediction system recognized a 34% ROI in only a week. As a subscriber, when you view your forecasts published daily, you can recognize better opportunities by looking for repetition of certain stock picks repeatedly remaining in the AI forecasts. Another indicator is when you see the stock pick appear in multiple forecasted time frames, especially over multiple forecasts published each morning EST.
Click here to see the original forecast published on November 14th, 2022.
The Signal Confidence (SC) in this stock forecast is 62%, which is quite high for only a monthly time frame. When combined with machine learning, these incredibly intricate mathematical functions for statistical programming and modeling are capable of comparing their current coefficients and algorithms to newly added data and then adapting to improve the models' accuracy through a process of validation and reflection. The AI system computes the Signal Confidence (SC), which is expressed as a percentage out of 100%, based on the historical accuracy of each previous financial asset prediction, as well as current market factors relevant to stock pricing.
Stock Ticker | Open: Nov 14, 2022 | Close: Dec 14, 2022 | ROI% |
Horizon Therapeutics (HZNP) | $73.70 | $113.13 | 53.50% |
Subscribers who bought HZNP stock based on our AI Forecast for the 1-month time frame on November 14th, 2022 would have generated a significant profit of 53.50% or $39.43 per share on this single trade. Discretion should always be used when analyzing the market. Your own due diligence is always required and you should always get advice from a licensed & certified financial counselor prior to implementing any financial plans.
Enhanced Market Intelligence
Finding market opportunities is made easier by using our AI system. It doesn't tell you what to do. It tells you where to look. Our skilled team of analysts carefully verifies the AI outputs and enhances this market research with a human touch, providing our subscribers with enhanced market intelligence. If you would like the AI advantage working for you, then you should subscribe today!
Life is better when you can be bullish.
Sources: 1. Horizon Therapeutics Investor Relations, "Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer" (2022)
2. UNITED STATES SECURITIES AND EXCHANGE COMMISSION, (FORM 8-K) (2022)
Hozzászólások